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Abstract: There is growing evidence that mesenchymal stem cell (MSC)-based immunosuppression
was mainly attributed to the effects of MSC-derived extracellular vesicles (MSC-EVs). MSC-EVs are
enriched with MSC-sourced bioactive molecules (messenger RNA (mRNA), microRNAs (miRNAs),
cytokines, chemokines, immunomodulatory factors) that regulate phenotype, function and homing
of immune cells. In this review article we emphasized current knowledge regarding molecular
mechanisms responsible for the therapeutic effects of MSC-EVs in attenuation of autoimmune and
inflammatory diseases. We described the disease-specific cellular targets of MSC-EVs and defined
MSC-sourced molecules, which were responsible for MSC-EV-based immunosuppression. Results
obtained in a large number of experimental studies revealed that both local and systemic administration
of MSC-EVs efficiently suppressed detrimental immune response in inflamed tissues and promoted
survival and regeneration of injured parenchymal cells. MSC-EVs-based anti-inflammatory effects
were relied on the delivery of immunoregulatory miRNAs and immunomodulatory proteins in
inflammatory immune cells (M1 macrophages, dendritic cells (DCs), CD4+Th1 and Th17 cells),
enabling their phenotypic conversion into immunosuppressive M2 macrophages, tolerogenic DCs
and T regulatory cells. Additionally, through the delivery of mRNAs and miRNAs, MSC-EVs
activated autophagy and/or inhibited apoptosis, necrosis and oxidative stress in injured hepatocytes,
neurons, retinal cells, lung, gut and renal epithelial cells, promoting their survival and regeneration.
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1. Introduction
Epidemiological studies revealed a significant increase in the incidence of autoimmune and
inflammatory diseases during the last two decades [1]. Accordingly, the total number of patients
taking immunosuppressive drugs has been continuously increasing [2]. Long-term administration
of immunosuppressive medications is inevitably associated with increased risk of infection and
malignancy due to the sustained suppression of anti-microbial and anti-tumor immunity [3]. Therefore,
new therapeutic agents, which could suppress detrimental immune response without causing
life-threatening immunosuppression are urgently needed for the treatment of autoimmune and
inflammatory diseases.
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Due to their capacity to modulate phenotype and function of immune cells, mesenchymal stem
cells (MSCs) have been considered as potentially new remedy for the treatment of autoimmune
and inflammatory diseases [4]. Although the large number of experimental and clinical studies
demonstrated beneficial effects of MSCs in alleviation of immune cell-driven, organ-specific and
systemic inflammatory disorders [4], several safety concerns related to the MSC-based therapy
has been raised [5]. Unwanted differentiation of transplanted MSCs and their possible malignant
transformation have been identified as the most important safety issues [5]. Additionally, patients
suffering from inflammatory bowel diseases (IBDs) and idiopathic pulmonary fibrosis (IPF) who
received immunosuppressive drugs just before MSC injection developed severe respiratory and
gastrointestinal infections, indicating that MSCs should not be used immediately after or in combination
with other immunosuppressive agents [6–8]. Autologous transplantation of MSCs is difficult to attempt
on patients with fulminant diseases because of a long cell preparatory period and cell transplantation
timing. Therefore, allogeneic MSCs have been used for the attenuation of acute and fulminant
inflammation [4]. However, MSCs express major histocompatibility complex (MHC) class I molecules
and may elicit strong allogeneic immune responses in MHC-class I-mismatched recipients that could
result in life-threatening aggravation of on-going inflammation [9].
A large number of experimental and clinical studies revealed that most of MSC-based
immunomodulatory effects were attributed to the immunoregulatory properties of MSC-sourced
secretome, which consists of a soluble component and encapsulated extracellular vesicles (MSC-EVs):
apoptotic bodies, microvesicles and exosomes (MSC-Exos) [10]. Subcellular particles derived from dead
or dying MSCs might contribute to the therapeutic efficacy of transplanted MSCs [11]. Accordingly,
during the apoptotic loss of MSCs, MSC-derived immunoregulatory factors are within large EVs
(apoptotic bodies with diameter >1000 nm) delivered to the phagocytes, inducing alteration in their
phenotype and function [11–13]. Microvesicles (100–1000 nm) and Exos (30–200 nm) are nano-sized
MSC-sourced EVs, which are, after the budding from the plasma membrane, released into the
extracellular milieu where it exerts biological effects in a paracrine and endocrine manner [14].
MSC-derived EVs express several adhesion molecules (CD29, CD44 and CD73), which enable
their homing to the injured and inflamed tissues. In the mouse model of acute kidney injury (AKI),
MSC-EVs were mainly accumulated in the inflamed kidneys [15], while in an intracerebral hemorrhage
model, MSC-EVs were detected in the injured brains [12]. Nevertheless, most of intravenously injected
MSC-EVs accumulate in the liver, spleen and the lungs where the mononuclear phagocyte system (MPS)
is active [12]. Clearance of EVs from the circulation was much slower in macrophage-depleted mice,
indicating the important role of MPS in EVs biodistribution. Therefore, several research groups used a
membrane-editing technology to induce surface modifications of MSC-EVs in order to increase their
chances for reaching the target cells before being taken up by the MPS. Alvarez and colleagues increased
neurotropism of EVs by modifying their membrane protein Lamp2B with Rabies viral glycoprotein
(RVG), which specifically binds to the acetylcholine receptors on neuronal cells. Accordingly, EVs
displaying the RVG protein more specifically targeted neuronal cells and showed better therapeutic
effects in attenuation of Alzheimer’s disease than naïve EVs [16]. Kooijman and coworkers used
glycosylphosphatidylinositol (GPI), a glycolipid, which is integrated into the EV’s membrane during
their biogenesis, to incorporate chemokine receptors, enzymes, antibodies and signaling molecules on
EV’s membranes, enhancing their tropism and therapeutic potential [17].
MSC-EV’s membrane is enriched in cholesterol, sphingomyelin, ceramide and lipid raft proteins [9]
enabling membrane fusion with target cells and trafficking of MSC-EVs through the body, regardless
of biological barriers [10]. It was suggested that MSC-EVs, in a similar manner as tumor-derived EVs,
crossed the blood–brain barrier (BBB) and that transcytosis is the main underlying mechanism [18].
Endothelial recycling endocytic pathway is involved in the transcellular transport of EVs [19].
Transcytosis through the brain endothelial cells includes clathrin-dependent and caveolin-independent
endocytosis of EVs, their intracellular trafficking (driven by Rab11-expressing recycling endosomes)
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and vesicle associated membrane protein (VAMP)-3/Snap23/syntaxin 4-dependent release of EVs into
the extracellular environment [20].
Upon reaching their target cells, MSC-EVs may trigger signaling via the receptor–ligand interaction,
or be internalized by endocytosis to deliver their content [21]. All MSC-EVs are enriched with
MSC-sourced bioactive molecules (messenger RNA (mRNA) and microRNAs (miRNAs)), enzymes,
cytokines, chemokines, immunomodulatory and growth factors) that regulate phenotype, function,
survival and homing of immune cells [14]. Accordingly, immunosuppressive effects elicited by
MSC-EVs were similar to those observed after transplantation of MSCs [10]. As a cell-free product,
MSC-derived EVs overcomes all safety concerns related to the long-term survival of engrafted MSCs,
including their un-controlled differentiation, malignant alteration or rejection due to the activation
of allogeneic immune response in MHC-mismatched recipients [14]. Importantly, composition of
MSC-EVs can be modulated by MSCs’ preconditioning in vitro, enabling generation of disease-specific,
MSC-based, immunosuppressive product, which could be used as a new remedy in cell-free treatment
of autoimmune and inflammatory diseases [14].
In this review article we emphasized current knowledge regarding molecular and cellular
mechanisms responsible for the therapeutic effects of MSC-EVs in attenuation of autoimmune and
inflammatory diseases. We described the disease-specific cellular targets of MSC-EVs and defined
MSC-sourced molecules, which were mainly responsible for MSC-EV-based protection of injured cells
and/or immunosuppression. An extensive literature review was carried out in October 2019 across
several databases (MEDLINE, EMBASE, Google Scholar, ClinicalTrials.gov), from 1991 to present.
Keywords used in the selection were: “mesenchymal stem cells (MSCs)”, “extracellular vesicles (EVs)”,
“exosomes (Exos)”, “inflammation”, “macrophages”, “dendritic cells”, “neutrophils”, “T cells”, “gut
epithelial cells”, “hepatocytes”, “hepatic stellate cells”, “lung epithelial cells”, “renal tubular cells”,
“retinal cells”, “neurons” and “cardiomyocytes”. All journals were considered, and an initial search
retrieved 1837 articles. The abstracts of all these articles were subsequently reviewed by three of the
authors (CRH, VD and VV) to check their relevance to the subject of this manuscript. Eligible studies
had to delineate molecular and cellular mechanisms involved in the beneficial effects of MSC-derived
EVs and their findings were analyzed in this review.
2. Macrophages: The Main Cellular Targets of MSC-Derived EVs in Alleviation of
Colon Inflammation
Macrophages have been identified as the most important cells for the induction of colon
inflammation [22,23]. Massive release of damage-associated molecular patterns (DAMPs) from
injured epithelial cells activates NF-κB signaling pathway in colon macrophages, resulting in increased
expression of inducible nitric oxide synthase (iNOS) and enhanced secretion of inflammatory cytokines
(tumor necrosis factor alpha (TNF-α), IL-1β), nitric oxide (NO) and lymphocyte and monocyte-recruiting
chemokines (CCL-17 and CCL-24) [24]. Macrophage-derived TNF-α and IL-1β induce enhanced
expression of E and P selectins on endothelial cells enabling massive influx of circulating monocytes and
lymphocytes in the injured gut [22]. Macrophage-sourced CCL-17 and CCL-24 attract inflammatory
M1 macrophages and IFN-γ producing CD4+Th1 cells, which either directly damage epithelial cells
(NO-producing M1 macrophages) or activate macrophages in IFN-γ-dependent manner (Th1 cells)
and indirectly promote colon injury and inflammation by enabling creation of “positive inflammatory
loop” in the gut [22].
Several recently published studies indicated that MSC-based alleviation of colitis was mainly relied
on MSC-EV-induced suppression of colon macrophages [25–28] (Figure 1). Cao and colleagues showed
that MSC-EVs significantly alleviated dextran sulphate sodium (DSS)-induced colitis in mice by inducing
polarization of colon macrophages in immunosuppressive, M2 phenotype [25]. Higher number of
IL-10-producing M2 macrophages, observed in MSC-EVs-treated mice, correlated with reduced
weight loss, alleviated injury of gut epithelial cells and increased colon length [25]. Concentration
of macrophage-sourced inflammatory cytokines and chemokines (TNF-α, CCL-17 and CCL-24) and
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Th1-derived IFN-γ were significantly attenuated in the gut of DSS-treated mice that received MSC-EVs.
Additionally, MSC-EVs managed to increase colon concentration of immunosuppressive cytokines
(IL-10 and transforming growth factor beta (TGF-β)), enabling enhanced repair and regeneration of
DSS-injured epithelial cells [25]. Importantly, in vitro obtained results confirmed that MSC-EVs entered
in lipopolysaccharides (LPS)-activated colon macrophages, suppressed production of inflammatory
cytokines and induced generation of immunosuppressive M2 phenotype [25].
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on the suppression of NF-κB and iNOS-driven signaling [26,27]. Administration of MSCs-EVs
down-regulated expression of NF-κB p65 and reduced production of NO, IL-1β and IL-18 in colon
acrophages, resulting in alleviated 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced colitis [26,27].
Wu and coworkers suggested that microRNA-146a (miR-146a), a well-known anti-inflammatory
miRNA, acted as a negative feedback regulator of colon macrophages in MSC-EV-based alleviation
of gut inflammation [27]. Administration of EVs, obtained from miR-146-overexpressing MSCs,
inhibited TNF receptor-associated factor 6 (TRAF6) and IL-1 receptor-associated kinase 1 (IRAK1)
expression, down-regulated phosphorylation of NF-κB p65 and inhibited generation of inflammatory
phenotype in macrophages, attenuated production of TNF-α, IL-1β, IL-6 and reduced colon injury and
inflammation [27].
Yang and colleagues suggested that odulation of anti-oxidant/oxidant balance in the injured
gut as responsible for MSC-EVs-induced effects on macrophage phenotype and function [26].
MSC-EV-mediated suppression of NO-driven injury in the gut was accompanied by decreased activity
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of myeloperoxidase and malondialdehyde and increased superoxide dismutase and glutathione activity.
Furthermore, MSC-EVs reduced cleavage of caspase-3, -8 and -9 and alleviated release of DAMPs from
injured gut epithelial cells, resulting in attenuated activation of NF-κB signaling pathway in colon
macrophages, which consequently led to the generation of immunosuppressive M2 phenotype [26].
Mao and coworkers suggested that, in addition to the inhibition of NF-κB and iNOS, MSC-EVs
exert their beneficial effects in colitis through the inhibition of IL-7 signaling in colon macrophages, as
well [28]. IL-7 displays strong chemotactic property for circulating monocytes enabling their massive
accumulation in inflamed tissues [29]. Additionally, IL-7 induces increased production of NO, TNF-α
and IL-1β in macrophages, enhancing their inflammatory properties [29]. MSC-EVs contain miR17,
which impairs IL-7:IL-7 receptor signaling by preventing synthesis and transactivation of Janus kinase
1 [30,31]. In line with these findings, MSC-EVs treatment significantly reduced activation of IL-7 and
iNOS-signaling pathways in colon macrophages, resulting in attenuated production of TNF-α, IL-1β,
IL-6 and increased secretion of IL-10, which led to the alleviation of colitis [28].
3. Molecular Mechanisms Responsible for MSC-EVs-Based Protection of Hepatocytes in Acute
Liver Injury and Fibrosis
As recently evidenced by us and others, MSC-derived secretome efficiently attenuated acute liver
failure and liver fibrosis in mice by suppressing major effector cells: natural killer T cells (NKT) cells in
fulminant hepatitis and CD4+ T helper lymphocytes and hepatic stellate cells (HSCs) in fibrosis [32–36].
MSC-sourced secretome contains high concentration of NO and reactive nitrogen species, which
decrease proliferation of liver NKT cells [37]. Accordingly, administration of MSC-derived secretome
significantly reduced total number of inflammatory NKT cells in the injured livers of mice with
fulminant hepatitis [32,34]. Additionally, MSC-derived secretome contains Kynurenine, which
maintains immunosuppressive phenotype of FoxP3-expressing NKT cells in the inflamed livers and
suppress their transdifferentiation in inflammatory, IL-17-producing NKT17 cells [34]. Liver NKT
cells cultured in the presence of MSC-sourced secretome have reduced capacity for production of
hepatotoxic (TNF-α) and inflammatory cytokines (IFN-γ, IL-17) [32,34]. Moreover, reduced expression
of molecules, which are responsible for NKT cell-dependent apoptosis of hepatocytes (Fas ligand,
CD107a and NKG2D) was observed in liver NKT cells cultured in the presence of MSC-derived
secretome [34].
In addition to immunosuppressive effects against NKT cells, MSC-sourced secretome may directly
protect hepatocytes from cell death [38,39]. Injection of human menstrual blood-derived MSC-Exos
significantly attenuated d-galactosamine/lipopolysaccharide (d-GalN/LPS)-induced acute liver injury
and increased survival rate of experimental mice by suppressing caspase-3-driven apoptosis of
hepatocytes [38]. In line with these findings are results obtained by Chen and colleagues who provided
additional evidence of anti-apoptotic capacity of MSC-EVs in a murine model of autoimmune hepatitis
(AIH) [39]. Hepatoprotective effects of MSC-Exos were relied on suppression of NLRP3-dependent
activation of caspase-1 and on inhibition of caspase-1-driven pyroptosis, characterized by plasma
membrane rupture, cytoplasmic swelling, osmotic lysis, DNA cleavage and massive release of
pro-inflammatory cytokines (IL-1β and IL-18) [40]. Accordingly, by suppressing pyroptosis, MSC-Exos
inhibited cell death of hepatocytes and attenuated IL-1β and IL-18-driven inflammation. MSC-derived
miR-233 was crucially important for these hepatoprotective effects of MSC-Exos since administration of
Exos derived from miR-233 deficient MSCs did not attenuate AIH [39]. The analysis of NLRP3-signaling
pathway revealed that exosomal miR-233 suppressed NLRP3:caspase-1-induced pyroptosis by
inducing degradation of NLRP3 mRNA in hepatocytes [39]. MSC-Exos attenuate oxidative stress
in inflamed livers, as well [41]. MSC-Exo-derived glutathione peroxidase 1 (GPX1) was mainly
responsible for MSC-Exo-dependent suppression of reactive oxygen species (ROS) formation in injured
hepatocytes [41].
In addition to their hepatoprotective effects, MSC-Exos may induce proliferation of hepatocytes. As
recently evidenced by Du and colleagues intravenous injection of Exos, obtained from human-induced
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pluripotent stem cell-derived MSCs (hiPSC-MSCs-Exos) attenuated hepatic ischemia-reperfusion (I/R)
injury by suppressing necrosis of hepatocytes and by promoting their proliferation [42]. The serum
levels of hepatocyte injury markers (aspartate aminotransferase (AST) and alanine aminotransferase
(ALT) were significantly lower and the expression levels of proliferation markers (proliferation
cell nuclear antigen (PCNA) and phosphohistone-H3 (PHH3)) were greatly increased in the livers
of I/R-injured mice that received hiPSC-MSCs-Exos [42]. Significantly increased proliferation of
hiPSC-MSCs-Exos-treated primary hepatocytes and HL7702 human hepatocytes was confirmed
in vitro. Mechanistically, hiPSC-MSCs-Exos directly fused with target hepatocytes or HL7702 cells and
increased the activity of sphingosine kinase (SK1) resulting in synthesis of sphingosine-1-phosphate
(S1P), which promoted hepatocyte growth, survival and proliferation [42,43]. This phenomenon was
completely abrogated after inhibition of either SK1 or S1P receptor, confirming crucial importance of
SK1/S1P signaling for hiPSC-MSCs-Exos-induced enhanced proliferation of hepatocytes [42].
Several lines of evidence demonstrated that MSC-EVs protected hepatocytes during chronic liver
inflammation and fibrosis, as well [44]. Results obtained by Li and colleagues showed that human
umbilical cord-MSCs-derived Exos attenuated carbon tetrachloride (CCl4)-induced liver fibrosis in
mice, as evidenced by recovered serum AST levels and reduced deposition of collagen type I and
III in the liver [44]. Significantly decreased expression of TGF-β1 and phosphorylated Smad2 was
observed in the CCl4-injured livers of MSC-Exo-treated mice, indicated that MSC-Exo-dependent
inhibition of TGF-β1 signaling pathway in hepatocytes was crucially important for anti-fibrotic
effects of MSC-Exos. Upon phosphorylation, Smad2 formed complexes with phosphorylated Smad3
and Smad4 and, subsequently, translocated into the nucleus to regulate the transcription of genes
responsible for epithelial-to-mesenchymal transition (EMT) of hepatocytes [45]. Significant increase in
E-cadherin-positive cells and decrease in N-cadherin- and vimentin-positive cells in MSC-Exo-treated
fibrotic livers, suggested that MSC-Exos prevented TGF-β1/Smad2-induced EMT of hepatocytes [44].
This hypothesis was confirmed in vitro. MSC-Exos completely reversed spindle-shaped morphology
and abrogated expression of EMT-associated markers in HL7702 human hepatocytes that underwent
EMT after treatment with recombinant TGF-β1 [44].
MSC-EVs attenuated chronic liver inflammation by suppressing production of inflammatory
cytokines (TNF-α, IL-1β and IL-6) and pro-fibrotic TGF-β1in liver macrophages (Kupffer cells), while
HSCs were the main cellular targets in MSC-EVs-based alleviation of liver fibrosis [46]. Through
the production of inflammatory cytokines and monocyte and lymphocyte-attracting chemokines,
Kupffer cells attract circulating leucocytes in inflamed liver contributing to the progression of
inflammation [47]. Furthermore, through the production of TGF-β1, Kupffer cells induce enhanced
expression of pro-fibrotic genes (collagen I, vimentin, α-SMA and fibronectin) in HSCs, resulting in
the development of liver fibrosis [47]. In line with these findings, Qu and coworkers engineered
miRNA-181-5p-overexpressing adipose tissue derived MSCs (MSCsmiRNA-181-5p), which produced
Exos that efficiently alleviated liver fibrosis by affecting survival and pro-fibrotic function of HSCs [48].
MSCsmiRNA-181-5p-Exos promoted expression of autophagy-related Beclin-1 and inhibited expression of
anti-apoptotic Bcl-2 in HSCs, resulting in increased apoptosis and autophagy of HSCs in fibrotic livers.
Furthermore, MSCsmiRNA-181-5p-Exos significantly down-regulated expression of pro-fibrotic genes
(collagen I, vimentin, α-SMA and fibronectin) in HSCs, which led to the attenuation of CCl4-induced
liver fibrosis in MSCsmiRNA-181-5p-Exos-treated mice [48].
4. MSC-EVs as Next-Generation Therapeutics for the Treatment of Lung Inflammatory Diseases
There is growing evidence that MSC-EVs protect lung epithelial cells from reactive oxidative
species and proteolytic enzymes released by lung-infiltrating neutrophils and monocytes [49–52].
Li and colleagues demonstrated that MSC-EV-based protection of lung epithelial cells against
oxidative stress-induced cell death is dependent on anti-apoptotic properties of miR-21-5p [50].
Intratracheal administration of MSC-Exos inhibited both intrinsic and extrinsic apoptotic pathways in
lung epithelial cells. However, pre-treatment of MSCs with miR-21-5p antagomir completely abrogated
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MSC-Exos-mediated suppression of caspase-3, -8 and -9 and diminished MSC-Exo-based protective
effects [50]. Western blot analysis revealed that pro-apoptotic phosphatase and tensin homolog (PTEN)
and programmed cell death protein 4 (PDCD4) were the main targets of MSC-derived miR-21-5p since
their expression was significantly decreased in lung epithelial cells of MSC-Exo-treated mice. When
I/R-injured mice received Exos derived from miR-21-5p-antagomir-treated MSCs, expression of PTEC
and PDCD4 and apoptosis of lung epithelial cells were not reduced, indicating crucial importance of
miR-21-5p-dependent suppression of PTEN and PDCD4 for anti-apoptotic effects of MSC-Exos in I/R
lung injury [50].
In addition to their anti-oxidative effects, MSC-EVs may protect lung epithelial cells by regulating
protease/antiprotease balance in the inflamed lungs [51]. Alpha-1-antitrypsin (AAT) is a potent inhibitor
of neutrophil-derived proteolytic enzymes, which protects lung epithelial cells and exerts important
anti-inflammatory and immunomodulatory effects in the lungs [52]. Most recently, Bari and colleagues
revealed that AAT was aggregated and/or adsorbed on the surface of adipose-tissue derived MSC-EVs
that served as natural carriers of AAT, promoting its stability and activity in vivo [51]. Importantly,
MSC-EVs derived from IL-β-primed MSCs showed significantly higher expression of AAT gene and
had increased anti-elastase activity compared to MSC-EVs obtained from IL-β-non-primed MSCs [51].
Importantly, MSC-EVs, in addition to AAT, contained 46 proteins involved in the response
to Gram-negative bacteria, implying potent anti-microbial activity of MSC-EVs [51]. In line with
these findings are results obtained by Hao and colleagues who demonstrated that administration
of MSC-EVs remarkably reduced severity of bacterial pneumonia in mice [53]. MSC-EVs increased
phagocytic and anti-microbial activity of lung-infiltrating neutrophils and monocytes by promoting
synthesis of leukotriene B4 (LTB4) [53]. LTB4 is well-known activator of leucocytes, which augments
phagocytosis and promotes release of anti-microbial agents, contributing to the bacterial clearance [54].
Hao and colleagues demonstrated that miR-145, contained within MSC-EVs, reduced expression of
multidrug resistance-associated protein 1 (MRP1) in lung macrophages [53]. MRP1 is ATP-binding
cassette transporter, which inhibits synthesis and release of LTB4 [53]. Accordingly, MSC-EV-induced
suppression of MRP1 resulted in enhanced release of LTB4 by alveolar macrophages that, due to its
anti-microbial activity, increased bacterial clearance and reduced severity of bacterial pneumonia in
mice [53].
It is important to highlight that capacity of MSC-EVs to modulate phenotype and function of
alveolar macrophages depends on the phase of anti-microbial inflammatory response [55]. During the
onset of inflammation, MSC-EVs, in a miR-145/LTB4-dependent manner, promote phagocytic activity of
alveolar macrophages contributing to the elimination of bacterial pathogens from the lungs. However,
during the resolution of inflammation, MSC-EVs promote expansion of alternatively activated M2
macrophages that are involved in tissue repair and regeneration [55]. It is well known that alveolar
macrophages, through the production of inflammatory cytokines and chemokines, orchestrate influx
of circulating monocytes and lymphocytes in inflamed lungs, promoting chronic inflammation [55].
Therefore, MSC-EV-based suppression of chronic, macrophage-driven inflammatory lung diseases was
mainly relied on MSC-EV-dependent polarization of alveolar macrophages. MSC-Exos significantly
decreased iNOS mRNA expression and remarkable increased expression of Arginase-1 mRNA in
alveolar macrophages, inducing their polarization from inflammatory M1 towards immunosuppressive
M2 phenotype [50,55]. Accordingly, concentration of M1-related inflammatory cytokines (IL-8,
IL-1β, IL-6 and TNF-α) was significantly reduced and concentration of M2 macrophage-derived
immunosuppressive cytokines (IL-10 and TGF-β) was increased in the lungs of I/R-injured mice that
received MSC-Exos [50].
Interestingly, as recently revealed by Huang and colleagues, aging MSC-EVs did not manage to
induce generation of M2 macrophages in the inflamed lungs [56]. Although aging and young MSC-EVs
had similar phenotypic characteristics (expression of CD63, CD81, CD105 and CD44), their capacity
to alter the phenotype of alveolar macrophages was different. Internalization of aging MSC-EVs by
alveolar macrophages was significantly lower compared to the young MSC-EVs. Furthermore, aging
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MSC-EVs had reduced capacity to inhibit production of inflammatory, M1-related cytokines (IL-6,
IL-1β and TNF-α) and to induce expression of M2-related Arginase-1 in alveolar macrophages [56].
Most importantly, aging and young MSC-EVs differed in levels of miRNAs (miR-223-5p, miR-127-3p
and miR-125b-5p) that regulate macrophage polarization. Compared with aging MSC-EVs, young
MSC-EVs showed higher expression of miR-223-5p (which is responsible for induction of M2 phenotype
in alveolar macrophages) and lower expression of miR-127-3p and miR-125b-5p (which promote
generation of M1 phenotype in macrophages) [56]. Since aging MSC-Exos had significantly reduced
capacity to attenuate M1 macrophage driven inflammation in the lungs, MSC-Exos used for the therapy
of inflammatory lung diseases should be obtained only from young donors.
Mansouri and colleagues recently revealed that single intravenous administration of Exos, obtained
from human bone marrow-derived MSC, managed to significantly attenuate bleomycin-induced lung
fibrosis in mice through the modulation of phenotype and function of alveolar macrophages [57]. An
improved Ashcroft score and reduced deposition of collagen were observed in bleomycin-injured
lungs of MSC-Exo-treated animals. MSC-Exo-based alleviation of fibrosis was followed by significantly
reduced number of TGF-β1-producing, Arginase-1 and CD206-expressing alveolar macrophages,
indicating that macrophages were the main cellular targets of MSC-Exos in alleviation of pulmonary
fibrosis. Importantly, anti-fibrotic effects were not observed in bleomycin-injured mice that received
fibroblasts-derived Exos or Exos free iodixanol, suggesting that immunomodulatory properties of
MSCs were responsible for beneficial effects of MSC-Exos [57].
In addition to alveolar macrophages, MSC-EVs may also modulate phenotype and function of
lung-infiltrating dendritic cells (DCs) [58]. As recently evidenced by Cho and colleagues, MSC-EV-based
alleviation of Th2 cell-driven immune response against Aspergillus protease antigen was dependent on
suppression of antigen-presenting properties of DCs [45]. MSC-Exos induced increased expression of
immunosuppressive IL-10 and TGF-β that suppressed maturation of lung DCs [58]. Immature DCs of
MSC-Exos-treated mice had reduced expression of co-stimulatory molecules (CD40, CD80 and CD86)
and were not capable to optimally activate CD4+Th2 cells, resulting in alleviation of Th2 cell-driven
lung inflammation [58].
The lung is a portal of entry for numerous microbial pathogens, which are, immediately after
invasion, captured and efficiently eliminated by alveolar macrophages and lung DCs, resulting in
the activation of antigen specific, T cell-driven immune response [59,60]. Upon activation, alveolar
macrophages and lung DCs produce large amount of inflammatory chemokines and cytokines and
orchestrate both local and systemic immune response [59]. Accordingly, lung macrophages and DCs
have been considered as the cells that are crucially important for the generation and development of
chronic inflammatory diseases [59]. Since most of intratracheally and intravenously administered
MSC-EVs accumulate in the lungs where, in similar manner as microbial pathogens, become phagocyted
by lung-infiltrated macrophages and DCs, capacity of MSC-EVs to modulate phenotype and function of
these professional antigen-presenting cells could be used not only for alleviation of inflammatory lung
diseases but also for modulation of detrimental macrophage and DC-driven systemic immune response.
5. Modulation of Microglial Activity: The Main Mechanism Responsible for
MSC-EVs-Dependent Attenuation of Neuroinflammatory Diseases
Microglia, the resident immune cells of the central nervous system (CNS), maintain tissue
homeostasis under physiological conditions [61]. However, after neuronal injury, microglia secrete
pro-inflammatory cytokines that either have direct neurotoxic effects or, in combination with
inflammatory chemokines, promote influx of circulating neutrophils in inflamed tissue [61]. An
excessive microglial activation damages the surrounding healthy neural tissue and induces the release
of alarmins and DAMPs from dead or dying neurons, which in turn, activates microglia enabling
creation of “positive inflammatory loop” in CNS, that results in a massive and progressive loss of
neurons [61]. In line with these findings, Ding and colleagues recently revealed that modulation
of microglial activity was the main mechanism responsible for beneficial effects of MSC-EVs in
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alleviation of Alzheimer’s disease (AD) [62]. Excessive accumulation of the amyloid-β peptide (Aβ)
in the brain is considered as the most common pathological characteristic of AD, which triggers
dysfunction of cognitive behavior [63]. Intravenously injected Exos, obtained from human umbilical
cord-derived MSCs, managed to reduce Aβ deposition and increased spatial learning and memory
function in AβPP/PS1 transgenic mice, used as murine model of AD [62]. Additionally, Bodart-Santos
and colleagues recently revealed that MSC-EVs prevented neuronal damage in AD by suppressing
oxidative stress-induced injury of hippocampal neurons [64]. Catalase was mainly responsible for
MSC-EV-based protection against ROS-induced injury since MSC-EVs with inactivated catalase were
unable to prevent ROS formation in hippocampal neurons [64]. MSC-Exos induced polarization of
microglia towards immunosuppressive M2 phenotype. Significantly higher number chitinase 3-like 3,
arginase-1 and mannose receptor C type 1 (MRC1)-expressing M2 microglia cells were found in the
brains of MSC-Exos-treated AβPP/PS1 mice [62]. M2 cells produce Aβ-degrading enzymes (neprilysin
(NEP) and insulin-degrading enzyme (IDE)) and anti-inflammatory cytokines (IL-10 and TGF-β),
contributing to the reduced Aβ deposition and alleviated inflammation [61]. Significantly increased
levels of NEP, IDE, IL-10 and TGF-β, and greatly reduced concentration of inflammatory cytokines
(TNF-α and IL-1β) were noticed in the brains of MSC-Exos-treated AβPP/PS1 mice, indicating that
MSC-Exos induce conversion of microglia from inflammatory M1 towards immunosuppressive M2
phenotype [62]. MSC-Exo-induced alternative microglial activation was confirmed in vitro, since
significantly higher concentration of IL-10 and TGF-β and lower concentration of TNF-α and IL-1β
were measured in supernatants of MSC-Exo-treated BV2 murine microglia cells [62].
Modulation of microglial activity was mainly responsible for beneficial effects of MSC-Exos in
alleviation of multiple sclerosis (MS), inflammation-mediated demyelinating disease [65]. Significantly
improved motor function was noticed in Theiler’s murine encephalomyelitis virus (TMEV)-infected
mice that received MSC-EVs [65]. Remarkably reduced number of Iba-1-positive microglia cells was
observed in the brains of TMEV+MSC-EV-treated mice compared to TMEV-only treated animals [65].
Importantly, MSC-EVs altered cytokine milieu in TMEV-infected mice. Significantly lower concentration
of microglia-derived inflammatory cytokines (TNF-α, IL-1-β, IL-18, IL-6 and IL-12) was noticed in
TMEV+MSC-EV-treated mice [65]. Furthermore, MSC-EVs significantly alleviated concentration of Th1
cell-derived IFN-γ and Th17 cell-sourced IL-17A, indicating that, in addition to microglia, MSC-EVs
suppressed inflammatory properties of brain-infiltrating inflammatory CD4+T cells, as well [65].
As recently revealed by Shiue and colleagues [66], continuous intrathecal injection of MSC-Exos
enabled functional recovery from nerve ligation-induced injury [66]. MSC-Exos suppressed production
of inflammatory cytokines (TNF-α and IL-1β) and promoted synthesis of anti-inflammatory cytokines
(IL-10 and TGF-β) in microglia, resulting in the alleviation of inflammation within the site of neural
injury [66]. The analgesic effects of MSC-Exos involved their actions on neurons, as well. MSC-Exos
delivered brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor in the
ipsilateral L5/6 dorsal root ganglion of nerve-ligated rats, enabling better recovery from nerve
ligation-induced injury [66]. Protein analysis demonstrated that vascular endothelial growth factor
C, angiopoietin-2 and fibroblast growth factor-2 were also present in the MSC-Exos, indicating that
induction of neo-angiogenesis may be, at least partially responsible for beneficial effects of MSC-Exos.
Importantly, immunofluorescence staining showed that MSC-Exos were presented in the ipsilateral L5
spinal dorsal horn, dorsal root ganglion and peripheral axons, suggesting a high homing ability of
MSC-Exos [66].
Huang and colleagues provided evidence that MSC-Exos ameliorated cerebral I/R injury by
preventing neural cell death through the inhibition of caspase-9 and caspase-3 [67]. MSC-sourced
pigment epithelium-derived factor (PEDF), which exhibits anti-inflammatory, antioxidative and
neuroprotective properties, was mainly responsible for beneficial effects of MSC-Exos [68]. Through the
delivery of PEDF, MSC-Exos increased expression of autophagy-associated protein LC3 and suppressed
caspase-3-driven apoptosis in neurons, significantly reducing I/R-induced injury [67]. Exos, obtained
from PEDF-overexpressing MSCs showed better therapeutic effects, while inhibition of autophagy
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significantly reduced neuroprotection elicited by PEDF-containing MSC-Exos, indicating crucial
importance of PEDF-induced autophagy for MSC-Exo-based attenuation of cerebral I/R injury [67].
6. Molecular Mechanisms Responsible for MSC-EVs-Based Renal Protection
MSC-EVs-dependent renal protection is relied on the inhibition of apoptosis, necrosis and
oxidative stress in renal tubular epithelial cells as well as suppression of detrimental immune response
in the kidneys (Figure 2) [69]. MSC-sourced mRNAs, miRNAs and immunosuppressive factors
were mainly responsible for beneficial effects of MSC-EVs in alleviation of acute and chronic renal
inflammation [69–80].
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renal protection during acute kidney injury (AKI) is relied on inhibition of apoptosis, necrosis and
oxidative stress and the promotion of autophagy in renal tubular epithelial cells as well as suppression
of detrimental immune response. Through the delivery of messenger RNAs (mRNAs), MSC-EVs
induce enhanced expression of ERK1/2 and promote survival of proximal tubular epithelial cells
(PTEC). MSC-EVs activated autophagy in PTEC and protected against cisplatin-induced AKI by
delivering trophic factor 14-3-3ζ, which interacted with ATG-16L, a protein essential for autophagy
induction. MSC-EVs enhanced activation of NF-E2-related factor 2/antioxidant responsive element,
decreased expression of NADPH oxidase and reduced producti n of reactive oxygen species in ischemic
kidneys and promote their regeneration. Additi ally, through the delivery of miR-21, MSC-EVs
significantly attenuated capacity for ntigen-presentation of ren l dendritic cells, which r sulted in
reduced activation of Th1 and Th17 cells alleviation of Th1 and Th17 cell-driven inflammation in
the kidneys. Through the delivery f microRNAs (miRNAs), particularly let-7b, MSC-EVs induced
conversion of inflammato y M1 macrophages into i munosuppressive M2 cells, which produ d
lower am unt of inflammatory cytokines (TNF-α and IL-1β) and chemokine CXCL1, resulting in
alleviated acute and chronic re al inflammation. MSC-sourced miRNA, particularly let-7c, targeted
pro-fibrotic genes (collagen IVα1, TGF-β1 and TGFβR ) i inflamed kidneys, crucially contrib t ng
to the therapeutic ffects of MSC-EVs in renal fibrosis. Additionally, neo-angiogenesis, i duc d by
MSC-d rived vascular endothelial growth factor (VEGF) was also responsible for beneficial effects of
MSC-EVs in alleviation of renal fibrosis.
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Several lines of evidence demonstrated that MSC-derived mRNAs were involved in
MSC-EVs-based attenuation of acute kidney injury (AKI) [70–73]. Bruno and colleagues noticed
significantly improved renal function in glycerol and cisplatin-injured kidneys of experimental
animals [70–72]. They revealed that mRNAs, which regulate transcription (e.g., CLOCK, IRF6 and
LHX6), cell cycle regulation (e.g., SENP2, RBL1 and CDC14B) and DNA/RNA repair (e.g., HMGN4,
TOPORS and ESF1) were contained within MSC-EVs and suggested that these MSC-derived mRNAs
were mainly responsible for increased proliferation and suppressed apoptosis of renal tubular cells
in cisplatin + MSC-EV-treated animals [70–72]. Pretreatment with ribonucleases (RNase) completely
abolished MSC-EVs-based renoprotection, confirming that MSC-derived mRNAs were crucially
involved in MSC-EV-dependent alleviation of AKI [70–72]. The same conclusion was made by Ju
and coworkers who observed that RNase treatment abolished MSC-EVs-induced overexpression of
ERK1/2 in renal tubular epithelial cells and completely abrogated therapeutic effects of MSC-EVs in
I/R-induced AKI [73].
In line with these findings are results reported by Gatti and colleagues who demonstrated that
MSC-EVs alleviated I/R-induced AKI by reducing apoptosis and by increasing proliferation of renal
tubular cells [74]. Similarly as it was observed by Bruno et al. [70] and Ju and et al [73], MSC-EV-based
renoprotection was diminished by RNase pretreatment [74], confirming the hypothesis that beneficial
effects of MSCs-EVs were mainly mediated by MSC-sourced mRNA.
Wang and colleagues indicated that activation of autophagy in proximal tubular epithelial cells
(PTEC) was responsible for greatly improved renal function of cisplatin + MSC-EVs-treated mice [75].
They showed that beneficial effects of MSC-EVs were completely abrogated by autophagy inhibitor,
3-methyladenine. Similarly, Jia and coworkers demonstrated that MSC-EVs activated autophagy in
cisplatin-injured PTEC and protected against AKI by delivering trophic factor 14-3-3ζ, which interacted
with ATG-16L, a protein essential for autophagy induction [76].
By using the I/R model of AKI, Zhou and colleagues indicated that attenuation of oxidative stress
was mainly responsible for MSC-EVs-based renoprotection in AKI [77,78]. This hypothesis was based
on enhanced activation of NF-E2-related factor 2/antioxidant responsive element, decreased expression
of NADPH oxidase and reduced production of ROS, which were observed in the I/R-injured kidneys
of MSC-EV-treated mice [77,78]. In line with these findings, Gu and coworkers observed preserved
mitochondrial morphology in renal tubular cells of MSC-EV-treated mice [79]. They showed that
miR-30 antagomirs remarkably reduced renoprotective effects of MSC-EVs, implying critical role of
miR-30 in MSC-EV-based attenuation of AKI [79]. Song and colleagues further emphasized importance
of MSC-derived miRNAs in renoprotection by demonstrating anti-inflammatory properties of miR-21
in alleviation of I/R-induced AKI [80]. MSC-sourced miR-21 reduced NF-κB activity in renal infiltrating
DCs and suppressed their maturation [80]. Accordingly, administration of miR-21-containing MSC-EVs
significantly attenuated capacity of renal DCs for production of inflammatory cytokines and reduced
activation of Th1 and Th17 cell-driven inflammation in I/R-injured kidneys leading to the attenuation
of AKI [80].
In addition to miR-21 and miR-30, members of the let-7 miR family, contained within MSC-EVs,
have been shown to regulate multiple genes involved in apoptosis and proliferation of renal tubular
epithelial cells, including CCNA2, CDC34, AURA/STK6, AURKB/STK12, E2F5, and CDK8 [81].
Moreover, MSC-derived let-7b was responsible for MSC-EV-induced generation of immunosuppressive
M2 phenotype in renal macrophages [82]. Accordingly, significantly lower concentration of M1-derived
inflammatory cytokines TNF-α and IL-1β were measured in I/R-injured kidneys of mice that received
let-7b-containing MSC-EVs.
MSC-sourced miRNAs, particularly let-7c, targeted pro-fibrotic genes (collagen IVα1, TGF-β1
and TGFβR1) in inflamed kidneys, crucially contributing to the therapeutic effects of MSC-EVs in
renal fibrosis and diabetic nephropathy [83–85]. In line with these findings were results obtained by
Zou and colleagues who indicated that MSC-EV-dependent down-regulation of CXCL1 production
was responsible for significantly decreased number of CD68+ macrophages in fibrotic kidneys
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of MSC-EVs-treated mice [84]. Since remarkably increased expression of MSC-sourced vascular
endothelial growth factor (VEGF) was observed in the MSC-EV-treated kidneys, Zou and coworkers
suggested that MSC-induced neo-angiogenesis was, in addition to MSC-EV-based immunosuppression,
also responsible for beneficial effects of MSC-EVs in alleviation of renal fibrosis [86]. Since activation
of MSCs with inflammatory cytokines (TNF-α and IFN-γ) significantly enhanced production of
immunosuppressive and pro-angiogenic factors in MSCs-Exos [87], TNF-α and IFN-γ-priming of
MSCs should be further explored as a new approach for the generation of MSC-EVs with optimal
renoprotective characteristics.
7. MSC-EV-Based Attenuation of Autoimmune and Inflammatory Eye Disease
A large number of experimental and clinical studies demonstrated beneficial effects of MSC-Exos
in the suppression of autoimmune and chronic inflammatory eye diseases [88–95]. Intravenous as well
as periocular administration of MSC-Exos efficiently attenuated experimental autoimmune uveitis
(EAU) [89,90]. MSC-Exos suppressed production of CCL2 and CCL21, which resulted in significantly
reduced presence of Gr-1-expressing granulocytes, CD68-expressing macrophages and CD4+T cells in
injured retinas [89]. While massive infiltration of inflammatory cells resulted in severe disruption of
the retinal photoreceptor layers in vehicle-treated EAU mice, only little structural damage of retinal
cells and few inflammatory infiltrates were observed in the eyes of MSC-Exo-treated EAU mice [90]. In
addition to their effect on chemokine production, MSC-Exos inhibited antigen-presenting function of
retinal-infiltrating DCs, as well. MSC-Exos significantly reduced expression of costimulatory molecules
(CD40, CD80 and CD86) and MHC class II proteins on DCs, attenuating their capacity for activation of
naive CD4+ T cells [90]. The transcript levels of DC-derived Th1 and Th17-related cytokines (IL-1β,
IL-6 and IL-12) were significantly lower in MSC-Exos-treated animals [90]. Accordingly, remarkably
reduced number of IFN-γ-producing Th1 and IL-17-producing Th17 cells, that play crucially important
pathogenic role in progression of EAU, were noticed in the eyes of MSC-Exo-treated EAU mice,
implying that therapeutic effects of MSC-Exos in alleviation of EAU were relied on suppression of Th1
and Th17 cell-driven inflammation [90].
Th17 cells are the main inflammatory, effector cells in dry eye disease (DED), chronic inflammatory
disease of the tears and ocular surface that is manifested by symptoms of discomfort, visual disturbance,
and tear film instability [91]. MSC-Exos contain a growth related oncogene (GRO), which suppresses
production of Th17-inducing cytokines (IL-1β, IL-6 and IL-23) in DCs and prevent Th17 cell-driven
inflammation [91,92]. In addition to GRO, MSC-sourced Indoleamine 2-3 dioxygenase (IDO) was
responsible for MSC-Exo-based suppression of DC-dependent generation of Th17 cells [93,94]. Exos
obtained from IDO-overexpressing MSCs down-regulated expression of co-stimulatory molecules and
suppressed production of Th17-inducing cytokines in DCs, attenuating their capacity for activation of
naïve T cells and generation of inflammatory Th17 cells [93,94]. Additionally, MSC-derived IDO acts as
a critical molecular switch that maintains immunosuppressive phenotype of FoxP3-exspressing Tregs
in inflamed tissues and prevents their re-programming into inflammatory Th17 cells [14]. Furthermore,
MSC-derived IDO promotes expansion of TGFβ and IL-10-producing- immunosuppressive Tregs,
contributing to the creation of immunosuppressive microenvironment in the inflamed eyes [88].
Accordingly, IDO-dependent regulation of Th17:T regulatory cells (Tregs) ratio, is also responsible
for MSC-Exo-based suppression of Th17 cell driven inflammation in the eyes [88]. In line with these
findings, we recently designed an ophthalmic solution (Exo-d-MAPPS), which activity was based on
therapeutic effects of GRO and IDO-containing MSC-Exos [94]. Exo-d-MAPPS treatment significantly
attenuated production of inflammatory cytokines in T cells and managed to alleviate dryness, grittiness,
scratchiness, irritation, burning and eye fatigue in DED patients [94].
In addition to their anti-inflammatory effects, MSC-Exos promoted repair and regeneration
of injured neurons in the eye [88]. Exos, obtained from bone marrow-derived MSCs, increased
survival and neuritogenesis of retinal ganglion cells (RGCs) [95]. By using nerve crush model,
Mead and Tomarev showed that intravitreal administration of MSC-Exos significantly reduced loss
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of RGCs and improved their function [95]. Therapeutic effects of MSC-Exos were relied on the
delivery of miR-17-92, miR21 and miR-146 into the injured RGCs. MSC-sourced miR-17-92 and
miR21 down-regulated expression of PTEN (an important suppressor of RGC axonal growth), while
MSC-derived miR-146a reduced expression of epidermal growth factor receptor (involved in inhibition
of axon regeneration) [95]. Importantly, beneficial effects of MSC-Exos in protection, repair and
regeneration of RGCs were observed only in animals that received MSC-Exos and were not noticed
after injection of fibroblasts-derived Exos [95], implying specific therapeutic potential of MSCs-Exos in
regeneration of injured RGCs. Since gradual loss of RGCs is the hallmark of glaucoma, MSC-Exos
represent potentially new therapeutic agents for glaucoma treatment, which efficacy should be explored
in up-coming clinical trials.
8. Delivery of MSC-Sourced mRNAs into the Injured Cardiomyocytes Was Mainly Responsible
for MSC-EVs-Based Cardioprotection
Several lines of evidence demonstrated that injection of MSC-EVs efficiently protected
cardiomyocytes from ischemic injury [96,97]. By using animal model of I/R-induced myocardial
injury, Lai and colleagues showed that Exos, isolated form human embryonic stem cells derived
MSCs, significantly reduced infarct size and remarkably improved cardiac function in experimental
animals [96]. MSC-Exos attenuated oxidative stress in I/R-injured hearts, as evidenced by greatly
increased tissue levels of ATP and nicotine adenine dinucleotide and significantly decreased levels
of reactive oxygen species [97]. MSC-Exos contain Parkinson protein 7/DJ-1 (DJ-1), which binds
to the PARKIN protein in oxidative stress conditions, protecting the mitochondria from oxidative
stress [98,99]. SinceDJ-1 protects murine heart from oxidative damage [100], MSC-sourced DJ-1 may be
responsible for MSC-Exo-based modulation of oxidative balance in ischemic hearts [96]. Accordingly,
Exos obtained from DJ-1-overexpressing MSCs should be explored in up-coming preclinical studies as
new agents that could promote cardiac regeneration after ischemic injury. Cardioprotective effects of
MSC-Exos were also relied on increased phosphorylation and activation of kinases that prevented
apoptosis of injured cardiomyocytes (Akt and Glycogen synthase kinase 3 (GSK3)) and on suppression
of c-Jun-N-terminal kinase, which promoted apoptosis in ischemic hearts [96].
Results obtained by Yu and coworkers supported the hypothesis that Akt kinase was the main
intracellular target for MSC-EV-based cardioprotection [97]. They showed that Exos, obtained from
Gata-4-overexpressing bone marrow derived MSCs, significantly reduced the size of ischemic lesion
and restored cardiac function in the rat model of acute myocardial infarction (AMI) by activating
Akt-dependent signaling pathway in injured cardiomyocytes [97]. Yu and colleagues revealed that
among several MSC-Exo-containing miRNAs that regulate survival and proliferation of cardiomyocytes,
miR-19a was mainly responsible for MSC-Exos-induced anti-apoptotic effects in ischemic hearts.
MSC-sourced miR-19a down-regulated activation of PTEN and promoted phosphorylation and
activation of Akt resulting in the up-regulation of anti-apoptotic Bcl-2 protein, resulting in reduced
apoptotic loss of cardiomyocytes [97]. In line with these findings are results obtained by Wang and
colleagues who demonstrated that Exos, obtained from endometrium-derived MSCs, significantly
improved recovery of cardiac function after AMI by promoting Akt-dependent up-regulation of
Bcl-2 activity in injured cardiomyocytes [101]. Wang et al. suggested that MSC-derived miR-21 was
mainly responsible for cardioprotective effects of MSC-EVs. They demonstrated that, in addition
to anti-apoptotic effects, miR21-containing MSC-Exos induced enhanced expression of vascular
endothelial growth factor (VEGF) and promoted neovascularization in ischemic hearts, significantly
improving cardiac function after AMI [101].
A crucially important role of MSC-sourced miRNAs for MSC-EV-based cardioprotection was
confirmed by Feng and colleagues [102]. They suggested that MSC-Exo-mediated delivery of miR-22
in ischemic cardiomyocytes was mainly responsible for improved cardiac function that was noticed
in MSC-Exo-treated mice with AMI [81]. Significantly reduced infarct size and cardiac fibrosis was
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a consequence of miR-22-dependent down-regulation of methyl-CpG-binding protein 2, epigenetic
regulator, which was up-regulated in ischemic hearts [102].
It should be emphasized that, in addition to their anti-apoptotic effects, MSC-EVs also suppressed
the influx of circulating leucocytes in injured hearts, contributing to the attenuation of on-going
inflammation [97]. Significantly reduced release of alarmins and DAMPs from MSC-EV-treated
cardiomyocytes resulted in decreased secretion of leucocyte-attracting chemokines by resident
macrophages. Accordingly, after reperfusion, a significantly lower number of neutrophils, monocytes
and lymphocytes infiltrated myocardium of MSC-Exo-treated animals, indicating that MSC-Exos-based
suppression of inflammatory response also contributed to the enhanced repair and regeneration of
injured cardiomyocytes [97].
9. Conclusions and Future Directions
MSC-EVs represent new, cell-free agents that could be used for efficient attenuation of
organ-specific and systemic inflammation. Both local and systemic administration of MSC-EVs
efficiently suppressed detrimental immune response in inflamed tissues and promoted survival and
regeneration of injured parenchymal cells.
Through the delivery of mRNAs and miRNAs, MSC-EVs activated autophagy and/or inhibited
apoptosis, necrosis and oxidative stress in injured hepatocytes, neurons, retinal cells, lung, gut and
renal epithelial cells, promoting their survival and regeneration. MSC-EVs-based anti-inflammatory
effects were relied on the delivery of immunoregulatory miRNAs and immunomodulatory proteins in
inflammatory immune cells (M1 macrophages, DCs and Th1/Th17 cells), enabling their phenotypic
conversion into anti-inflammatory and immunosuppressive cells (Table 1).
Table 1. Therapeutic effects of MSC-EVs in attenuation of inflammatory diseases.
Disease Model MSC Source Type ofMSC-EVs Target Cell Molecular Mechanism Therapeutic Effect Ref. No.
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Abbreviations: Dextran sulfate sodium (DSS); bone marrow (BM); umbilical cord (UC);
D-Galactosamine/Lipopolysaccharide (D-GalN/LPS); menstrual blood (MB); ischemia-reperfusion (I/R);
induced pluripotent stem cells (iPSC); sphingosine kinase (SK1); carbon tetrachloride (CCl4); amnion (AM); adipose
tissue (AT); hepatic stellate cells (HSCs); Escherichia coli (E. coli); leukotriene B4 (LTB4); dendritic cells (DCs);
amyloid-β peptide (Aβ); Alzheimer’s disease (AD); Wharton’s jelly (WJ); Theiler’s murine encephalomyelitis virus
(TMEV); multiple sclerosis (MS); cisplatin (CDDP); acute kidney injury (AKI); proximal tubular epithelial cells
(PTEC); Experimental autoimmune uveitis (EAU); retinal ganglion cells (RGCs); embryonic stem cells (ESCs); acute
myocardial infarction (AMI); endometrium (EM); vascular endothelial growth factor (VEGF).
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It should be noted that although experimental findings strongly suggested therapeutic potential
of MSC-EVs, there is still a lot of experimental work to be done before MSC-EVs could be offered as
universal human remedy for the therapy of inflammatory diseases.
MSC-EVs exhibit most of the properties of MSCs and fundamental challenges relating to
MSC heterogeneity affect biological properties and therapeutic potential of MSC-EVs, as well [103].
Differences in the proliferation rate, potential for multi-lineage differentiation and immunosuppressive
properties of MSCs from different sources are well-documented [104]. Furthermore, even when MSCs
were obtained from the same tissue of origin, they could have prodigious donor-to-donor variation
in expression of membrane markers, transcriptional and proteomic profile [104]. Aging also has a
negative influence on self-renewal capacity, differentiation and immunosuppressive characteristics
of MSCs, attenuating their therapeutic potential [105]. In line with these findings, several recently
published studies indicated that MSC-EVs have significant tissue source and age-dependent differences
in their capacity for immunosuppression and tissue regeneration [106–108]. Additionally, culture
conditions in which MSCs were exposed may also influence the concentration of immunomodulatory
factors within MSC-EVs. Significantly higher concentration of immunosuppressive cytokines were
observed in EVs that were obtained from the MSCs, which were primed with inflammatory cytokines
(TNF-α and IFN-γ) than in EVs that were derived from MSCs, which were grown under standard
culture conditions [103].
Since large number of different mRNAs, miRNAs, anti-apoptotic and immunosuppressive proteins
have been proposed as crucially important for beneficial effects of MSC-EVs, further experimental
studies should identify the exact disease-specific MSC-sourced molecule(s) responsible for long-term
protection of injured cells and/or sustained immunosuppression. Additionally, the precise dose
and route of administration of MSC-EVs should be defined for each organ-specific and systemic
inflammatory disease in order to prevent the development of uncontrolled immunosuppression in
MSC-EVs recipients.
It should be noted that different laboratories use diverse methods to isolate and purify MSC-EVs
and, accordingly, it is critical to define and standardize highly effective method for MSC-EV yields [31].
Additionally, clinical applications of MSC-EVs require their long-term use and considerable thought
must be given to the preservation of their immunosuppressive potential [21]. A large number of
studies demonstrated that the most convenient mode of storage for MSC-EVs remains −80 ◦C [109].
Nevertheless, due to the complex cold chain logistics, alternatives such as lyophilization and
the incorporation of additives might be necessary to improve MSC-EV storage stability during
transportation [21,109].
In summing up, due to their unique biological and immunosuppressive properties, MSC-EVs
represents potentially new therapeutic agents in regenerative medicine. Once the critical questions
around isolation, long-term preservation, donor and tissue source of MSC-EVs are answered, MSC-EVs
will meet their full versatile potential as a new remedies in the therapy of inflammatory diseases.
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